Immunovaccine Retains B & D Capital Partners For Strategic Investor Relations Services

Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX VENTURE:IMV), a
clinical stage vaccine company, has retained B & D Capital Partners ("B & D") to
provide strategic investor relations services. B & D will aid the Company in
building awareness in the financial community by introducing, maintaining and
protecting relationships between the management of the Company and professional
investors. Based in Vancouver, British Columbia, the partners of B & D Capital
have been instrumental in raising more than $120 million through public and
private financings. Don Mosher, a principal in the company, holds shares in
Immunovaccine. 


Under the terms of the agreement with B & D, the Company will pay B & D a
monthly fee of $2,500. The consulting agreement is subject to the approval of
the TSX Venture Exchange. The agreement has a term of three months, unless
extended in writing, but may be terminated by either party with 30 days written
notice.


About Immunovaccine

Immunovaccine Inc. applies its novel technology to the development of vaccines
for cancer therapy, infectious diseases and animal health. The Company's
DepoVax(TM) platform is a patented formulation that provides controlled and
prolonged exposure of antigens plus adjuvant to the immune system. Immunovaccine
has advanced two DepoVax(TM)-based cancer vaccines into Phase I human clinical
trials. The Company is also advancing a broad infectious diseases pipeline
including vaccines in such indications as malaria, respiratory syncytial virus
(RSV) and anthrax. Connect at www.imvaccine.com.


This press release contains forward-looking information under applicable
securities law. All information that addresses activities or developments that
we expect to occur in the future is forward-looking information. Forward-looking
statements are based on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a representation
that any of the plans will be achieved. Actual results may differ materially
from those set forth in this press release due to risks affecting the company,
including access to capital, the successful completion of clinical trials and
receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press release. 


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Immunovaccine Inc.
Dr. Marc Mansour
Chief Operating Officer
(902) 492-1819
mmansour@imvaccine.com
www.imvaccine.com


Vida Strategic Partners (media)
Tim Brons
(415) 675-7402
tbrons@vidasp.com

(TSXV:IMV)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024